Next Article in Journal
Satisfaction with Telemedicine for Cancer Pain Management: A Model of Care and Cross-Sectional Patient Satisfaction Study
Previous Article in Journal
The Effect of Tobacco Smoke N-Nitrosamines, NNK and NDEA, and Nicotine, on DNA Mismatch Repair Mechanism and miRNA Markers, in Hypopharyngeal Squamous Cell Carcinoma: An In Vivo Model and Clinical Evidence
 
 
Article

Somatostatin Receptor Theranostics for Refractory Meningiomas

1
APHP, Pitié-Salpêtrière Hospital, Nuclear Medicine Department, Sorbonne University, 75013 Paris, France
2
INSERM, MMG, APHM, Timone Hospital, Neurosurgery Department, Aix-Marseille University, 13005 Marseille, France
3
APHM, Timone Hospital, Nuclear Medicine Department, Aix-Marseille University, 13005 Marseille, France
4
APHM, Timone Hospital, Neuro-Oncology Department, 13005 Marseille, France
5
APHM, Timone Hospital, Radiotherapy Department, 13005 Marseille, France
6
CERIMED, APHM, Timone Hospital, Nuclear Medicine Department, Aix-Marseille University, 13005 Marseille, France
7
CNRS, Centrale Marseille, Institut Fresnel, CERIMED, APHM, Timone Hospital, Nuclear Medicine Department, Aix-Marseille University, 13005 Marseille, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(8), 5550-5565; https://doi.org/10.3390/curroncol29080438
Received: 23 June 2022 / Revised: 31 July 2022 / Accepted: 1 August 2022 / Published: 4 August 2022
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy. The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 177Lu-DOTATATE and an overall analysis of progression-free survival at 6 months (PFS-6) of the same relevant studies in the literature. Eight patients with recurrent and progressive WHO grade II meningiomas were treated after multimodal pretreatment with 177Lu-DOTATATE between 2019 and 2022. Primary and secondarily endpoints were progression-free survival at 6-months (PFS-6) and toxicity, respectively. PFS-6 analysis of our case series was compared with other similar relevant studies that included 86 patients treated with either 177Lu-DOTATATE or 90Y-DOTATOC. Our retrospective study showed a PFS-6 of 85.7% for WHO grade II progressive refractory meningiomas. Treatment was clinically and biologically well tolerated. The overall analysis of the previous relevant studies showed a PFS-6 of 89.7% for WHO grade I meningiomas (n = 29); 57.1% for WHO grade II (n = 21); and 0 % for WHO grade III (n = 12). For all grades (n = 86), including unknown grades, PFS-6 was 58.1%. SSTR-targeted PRRT allowed us to achieve prolonged PFS-6 in patients with WHO grade I and II progressive refractory meningiomas, except the most aggressive WHO grade II tumors. Large scale randomized trials are warranted for the better integration of PRRT in the treatment of refractory meningioma into clinical practice guidelines. View Full-Text
Keywords: meningioma; peptide receptor radionuclide therapy; somatostatin receptor; treatment-refractory meningioma meningioma; peptide receptor radionuclide therapy; somatostatin receptor; treatment-refractory meningioma
Show Figures

Figure 1

MDPI and ACS Style

Salgues, B.; Graillon, T.; Horowitz, T.; Chinot, O.; Padovani, L.; Taïeb, D.; Guedj, E. Somatostatin Receptor Theranostics for Refractory Meningiomas. Curr. Oncol. 2022, 29, 5550-5565. https://doi.org/10.3390/curroncol29080438

AMA Style

Salgues B, Graillon T, Horowitz T, Chinot O, Padovani L, Taïeb D, Guedj E. Somatostatin Receptor Theranostics for Refractory Meningiomas. Current Oncology. 2022; 29(8):5550-5565. https://doi.org/10.3390/curroncol29080438

Chicago/Turabian Style

Salgues, Betty, Thomas Graillon, Tatiana Horowitz, Olivier Chinot, Laetitia Padovani, David Taïeb, and Eric Guedj. 2022. "Somatostatin Receptor Theranostics for Refractory Meningiomas" Current Oncology 29, no. 8: 5550-5565. https://doi.org/10.3390/curroncol29080438

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop